Purple Book reference family · 351(a) biologic
Antivenin (Micrurus fulvius)
Antivenin (Micrurus fulvius) is an FDA-licensed reference biologic from Wyeth Pharmaceuticals LLC.
351(a) biologicBLA 101099 Wyeth Pharmaceuticals LLC
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
1967
Reference product
Originator biologic
351(a)BLA 101099
Not listed Antivenin (Micrurus fulvius)
Wyeth Pharmaceuticals LLC
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Protection horizon
Reference approval
Approval date of the reference Antivenin (Micrurus fulvius) product.
59 yr 9 mo ago
Antivenin (Micrurus fulvius): frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Antivenin (Micrurus fulvius).
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
